EP0014815A3
(de)
|
1978-12-20 |
1980-10-29 |
Ciba-Geigy Ag |
Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
|
US4939240A
(en)
|
1983-03-04 |
1990-07-03 |
Health Research, Inc. |
Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
|
US4918164A
(en)
|
1987-09-10 |
1990-04-17 |
Oncogen |
Tumor immunotherapy using anti-idiotypic antibodies
|
DE3813821A1
(de)
|
1988-04-22 |
1989-11-02 |
Hoechst Ag |
Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
|
US6024964A
(en)
|
1985-06-24 |
2000-02-15 |
Hoechst Aktiengesellschaft |
Membrane anchor/active compound conjugate, its preparation and its uses
|
US6074650A
(en)
|
1985-06-24 |
2000-06-13 |
Hoechst Aktiengesellschaft |
Membrane anchor/active compound conjugate, its preparation and its uses
|
US4743543A
(en)
|
1985-09-09 |
1988-05-10 |
Coulter Corporation |
Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
|
US4921790A
(en)
|
1987-04-24 |
1990-05-01 |
Research Corporation |
Tumor specific assay for CA125 ovarian cancer antigen
|
US4963484A
(en)
|
1988-01-29 |
1990-10-16 |
Dana-Farber Cancer Institute, Inc. |
Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
|
US5053489A
(en)
|
1988-01-29 |
1991-10-01 |
Dana-Farber Cancer Institute, Inc. |
Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
|
US4914021A
(en)
|
1988-03-04 |
1990-04-03 |
New England Deaconess Hospital Corporation |
Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
|
US4921789A
(en)
|
1988-04-20 |
1990-05-01 |
New England Deaconess Hospital Corporation |
Marker for colorectal carcinoma and methods of detecting the same
|
JPH02172946A
(ja)
|
1988-12-26 |
1990-07-04 |
Shinetsu Sakusan Vinyl Kk |
カルボン酸アルケニルエステルの製造方法
|
US5110911A
(en)
|
1989-11-02 |
1992-05-05 |
Biomira, Inc. |
Human tumor-associated thomsen-friedenreich antigen
|
CA2131528C
(en)
|
1992-03-05 |
2004-07-13 |
Philip E. Thorpe |
Methods and compositions for targeting the vasculature of solid tumors
|
WO1994013806A1
(en)
|
1992-12-11 |
1994-06-23 |
The Dow Chemical Company |
Multivalent single chain antibodies
|
CA2154266A1
(en)
|
1993-02-05 |
1994-08-18 |
John F. Codington |
Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
|
US6310180B1
(en)
|
1993-06-21 |
2001-10-30 |
Vanderbilt University |
Method for synthesis of proteins
|
DE4331011A1
(de)
|
1993-09-13 |
1995-03-16 |
Bayer Ag |
Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
|
AUPM446594A0
(en)
|
1994-03-16 |
1994-04-14 |
Csl Limited |
Cytotoxic t-cell epitopes identified within epstein-barr virus
|
JPH08248579A
(ja)
|
1995-03-14 |
1996-09-27 |
Mitsubishi Paper Mills Ltd |
ハロゲン化銀写真感光材料及びその処理方法
|
US5994294A
(en)
|
1996-02-02 |
1999-11-30 |
Nitromed, Inc. |
Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
|
AUPO007396A0
(en)
|
1996-05-24 |
1996-06-20 |
Csl Limited |
Ebv ctl epitopes
|
US6251603B1
(en)
|
1996-10-03 |
2001-06-26 |
Ludwig Institute For Cancer Research |
Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
|
US6982085B2
(en)
|
1997-04-02 |
2006-01-03 |
Statens Serum Institut |
TB diagnostic based on antigens from M. tuberculosis
|
US7037510B2
(en)
|
1997-04-18 |
2006-05-02 |
Statens Serum Institut |
Hybrids of M. tuberculosis antigens
|
AUPO784197A0
(en)
|
1997-07-10 |
1997-08-07 |
Csl Limited |
Treatment of nasopharyngeal carcinoma
|
US5965535A
(en)
|
1997-09-12 |
1999-10-12 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
DE69837273T2
(de)
*
|
1997-10-08 |
2008-01-31 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
|
IL125608A0
(en)
|
1998-07-30 |
1999-03-12 |
Yeda Res & Dev |
Tumor associated antigen peptides and use of same as anti-tumor vaccines
|
US20040006242A1
(en)
|
1999-02-01 |
2004-01-08 |
Hawkins Lynn D. |
Immunomodulatory compounds and method of use thereof
|
JP4698027B2
(ja)
|
1999-02-01 |
2011-06-08 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
免疫アジュバント化合物
|
EP2311950A1
(en)
|
2000-01-28 |
2011-04-20 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
|
WO2002000623A2
(en)
|
2000-06-26 |
2002-01-03 |
Neurogen Corporation |
Aryl fused substituted 4-oxy-pyridines
|
US6506875B1
(en)
*
|
2000-09-26 |
2003-01-14 |
Ludwig Institute For Cancer Research |
Isolated peptides which bind to HLA-C molecules and uses thereof
|
GB0030067D0
(en)
|
2000-12-11 |
2001-01-24 |
Univ Bristol |
Therapeutic agent
|
EP1229043A1
(en)
|
2001-01-30 |
2002-08-07 |
Cyto-Barr B.V. |
Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
|
WO2003008537A2
(en)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
AU2002353485B2
(en)
|
2001-12-04 |
2009-01-15 |
Ben Gurion University Of The Negev Research And Development Authority |
Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
|
FR2836684B1
(fr)
*
|
2002-03-04 |
2004-12-17 |
Inst Nat Sante Rech Med |
Peptides ras mutes et leur utilisation en immunotherapie
|
NZ537579A
(en)
|
2002-06-10 |
2006-10-27 |
Vaccinex Inc |
C35 peptide epitopes and their analogs
|
GB0214528D0
(en)
|
2002-06-24 |
2002-08-07 |
Univ Aberdeen |
Materials and methods for induction of immune tolerance
|
WO2004006952A2
(en)
|
2002-07-13 |
2004-01-22 |
Statens Serum Institut |
Therapeutic tuberculosis vaccines
|
KR101151368B1
(ko)
|
2002-08-12 |
2012-06-08 |
더 카운실 오브 더 퀸스랜드 인스티튜트 오브 메디칼 리서어치 |
T-헬퍼 및 세포독성 t 림프구(ctl) 에피토프를포함하는 신규한 면역원성 리포펩타이드
|
DK1543039T3
(da)
|
2002-08-12 |
2011-10-31 |
Queensland Inst Med Res |
Nye immunogene lipopeptider omfattende T-hjælper- og B-celle-epitoper
|
TW200416043A
(en)
|
2002-11-07 |
2004-09-01 |
Queensland Inst Med Res |
Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
|
US7491395B2
(en)
|
2002-11-20 |
2009-02-17 |
Bestewil Holding B.V. |
Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
|
US20080139464A1
(en)
|
2003-05-30 |
2008-06-12 |
Ludwig Institute Of Cancer Research |
Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
|
WO2005012270A2
(en)
|
2003-07-29 |
2005-02-10 |
Rib-X Pharmaceuticals, Inc. |
Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
|
US20080199493A1
(en)
|
2004-05-25 |
2008-08-21 |
Picker Louis J |
Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
|
EP1666056A1
(en)
|
2004-12-06 |
2006-06-07 |
Bestewil Holding B.V. |
Cancer vaccine vesicles
|
FR2881746B1
(fr)
|
2005-02-07 |
2007-04-13 |
Centre Nat Rech Scient |
Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
|
US20080233143A1
(en)
|
2005-02-07 |
2008-09-25 |
Lipotek Pty Ltd. |
Adjuvanting Material
|
BRPI0607605A2
(pt)
|
2005-02-08 |
2009-09-15 |
Queensland Inst Med Res |
moléculas imunogênicas
|
GB0507003D0
(en)
*
|
2005-04-06 |
2005-05-11 |
Molmed Spa |
Therapeutic
|
KR20080030564A
(ko)
|
2005-05-12 |
2008-04-04 |
태피스트리 파마슈티컬스 인코퍼레이티드 |
표적 컨쥬게이트에 적합한 분자 구조물
|
JP2009510169A
(ja)
*
|
2005-10-04 |
2009-03-12 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
細菌抗原送達系を用いた免疫応答を刺激するための方法
|
CA2620899A1
(en)
|
2005-10-12 |
2007-04-19 |
Biolipox Ab |
Benzoxazoles useful in the treatment of inflammation
|
JP4824389B2
(ja)
|
2005-10-28 |
2011-11-30 |
株式会社医学生物学研究所 |
エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途
|
CA2632402A1
(en)
|
2005-12-06 |
2007-06-14 |
Savine Therapeutics Pty Ltd |
Treatment of epstein-barr virus-associated diseases
|
WO2007078879A2
(en)
|
2005-12-21 |
2007-07-12 |
Vaxinnate Corporation |
Lipopeptide compositions and methods of use thereof
|
FR2896162B1
(fr)
|
2006-01-13 |
2008-02-15 |
Sanofi Pasteur Sa |
Emulsion huile dans eau thermoreversible
|
US20090123488A1
(en)
|
2006-08-14 |
2009-05-14 |
Thymon, Llc |
Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
|
US8309096B2
(en)
*
|
2007-01-15 |
2012-11-13 |
Glaxosmithkline Biologicals S.A. |
Fusion protein
|
DK2118128T3
(da)
|
2007-01-15 |
2013-02-18 |
Glaxosmithkline Biolog Sa |
Fusionsproteiner omfattende tumorrejektionantigenerne NY-ESO-1 og LAGE-1
|
EP2462947B1
(en)
|
2007-03-26 |
2019-03-13 |
Academisch Ziekenhuis Leiden h.o.d.n. LUMC |
PRAME derived peptides and immunogenic compositions comprising these
|
WO2008151197A2
(en)
|
2007-06-04 |
2008-12-11 |
The Regents Of The University Of California |
Tumor-derived endogenous toll-like receptor 4 ligands
|
US20100266623A1
(en)
|
2008-07-07 |
2010-10-21 |
The University Of Melbourne |
Synthetic, self adjuvanting vaccines
|
EP2320882A4
(en)
|
2008-07-07 |
2014-12-31 |
Univ Melbourne |
SYNTHETIC VACCINE COMPONENT
|
CA2736187A1
(en)
*
|
2008-09-05 |
2010-03-11 |
Id Biomedical Corporation Of Quebec |
Novel compositions and adjuvants
|
US8436015B2
(en)
|
2008-09-15 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
WO2011063233A1
(en)
|
2009-11-23 |
2011-05-26 |
Amgen Inc. |
Amino heteroaryl compounds as beta-secretase modulators and methods of use
|
WO2011063272A1
(en)
|
2009-11-23 |
2011-05-26 |
Amgen Inc. |
Amino heteroaryl compounds as beta-secretase modulators and methods of use
|
US20130045203A1
(en)
|
2010-03-02 |
2013-02-21 |
Emory University |
Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
|
WO2011119628A2
(en)
|
2010-03-23 |
2011-09-29 |
The Regents Of The University Of California |
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
|
US20130029358A1
(en)
|
2010-04-01 |
2013-01-31 |
Ludwig Institute For Cancer Research Ltd. |
Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
|
WO2011156686A2
(en)
|
2010-06-11 |
2011-12-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
|
WO2012020215A1
(en)
|
2010-08-09 |
2012-02-16 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
|
ES2655535T3
(es)
|
2010-08-25 |
2018-02-20 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Una vacuna contra el virus de Epstein-Barr
|
EP2611905A4
(en)
|
2010-09-01 |
2014-02-12 |
Baylor College Medicine |
EBV-SPECIFIC CYTOTOXIC T LYMPHOCYTES FOR THE TREATMENT OF LOCO-REGIONAL NASOPHARYNX CARCINOMA (NPC)
|
BR112013005970A2
(pt)
|
2010-09-14 |
2016-07-05 |
Council Scient Ind Res |
imunógeno sintético, últil para gerar imunidade duradoura e proteção contra patógenos.
|
SI2618835T1
(sl)
|
2010-09-20 |
2017-10-30 |
Biontech Cell & Gene Therapies Gmbh |
Antigen-specifični t celični receptorji in t celični epitopi
|
AU2011305061B2
(en)
|
2010-09-22 |
2016-04-14 |
Ena Respiratory Pty Ltd |
Novel immunostimulatory method
|
WO2012069188A1
(en)
|
2010-11-24 |
2012-05-31 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V |
Continuous flow processes for photoconjugation of high-molecular chemical entities
|
US9187534B2
(en)
*
|
2011-03-11 |
2015-11-17 |
Universite De Geneve |
Multi-epitopic vaccine
|
DK2686020T3
(en)
|
2011-03-17 |
2017-05-01 |
Univ Birmingham |
REDIRECTED IMMUNTERY
|
EP2707356A4
(en)
|
2011-05-13 |
2014-10-15 |
Univ Nanyang Tech |
PROCESS FOR MODIFYING ORGANIC MOLECULES
|
US20120328660A1
(en)
|
2011-06-03 |
2012-12-27 |
Tsuji Takemasa |
Immunogenic compositions useful in provoking an integrated response to tumor antigens
|
CN102839186A
(zh)
*
|
2011-06-21 |
2012-12-26 |
上海生物制品研究所有限责任公司 |
表达ny-eso-1重组耻垢分枝杆菌的制备及应用
|
GB201114051D0
(en)
|
2011-08-15 |
2011-09-28 |
Domainex Ltd |
Compounds and their uses
|
US10406248B2
(en)
|
2011-09-10 |
2019-09-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Molecular imaging of cancer cells in vivo
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
SG11201401177WA
(en)
*
|
2011-10-06 |
2014-04-28 |
Immunovaccine Technologies Inc |
Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
|
US9056141B2
(en)
|
2012-05-31 |
2015-06-16 |
Synchem, Inc. |
Thiol-ene click chemistry for drug conjugates
|
US9861702B2
(en)
|
2012-10-22 |
2018-01-09 |
Wisconsin Alumni Research Foundation |
Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
|
CA2893918C
(en)
*
|
2012-12-06 |
2020-11-24 |
Callaghan Innovation Research Limited |
Conjugate compounds
|
CN105555756B
(zh)
|
2013-06-28 |
2018-12-07 |
奥克兰联合服务有限公司 |
氨基酸缀合物和肽缀合物及缀合方法
|
BR112017013574A2
(pt)
|
2014-12-23 |
2018-03-06 |
Verdon Daniel |
conjugados de aminoácido e peptídeo e usos dos mesmos
|
JP7161404B2
(ja)
|
2016-02-26 |
2022-10-26 |
オークランド ユニサービシーズ リミティド |
アミノ酸及びペプチド接合体及び接合方法
|